ReviewIntensive care medicine2020
Current and evolving standards of care for patients with ARDS.
Review in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Effect of therapeutic interventions combined with lung-protective ventilation on long-term mortality of patients with acute respiratory distress syndrome: a network meta-analysis.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2026Pooled it
- Quality of life following adult veno-venous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Pooled it
- Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients.The New England journal of medicine · 2023Trial
- Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial.Intensive care medicine · 2022Trial
- Lonicera japonica-Derived Nanovesicles Ameliorate Acute Lung Injury by Suppressing Neutrophil Extracellular Traps Formation in Mice.Advanced healthcare materials · 2026Article
- Nitric oxide exacerbates systemic inflammation in adults with severe acute respiratory.BMC pulmonary medicine · 2026Article
- Nursing interventions and multidomain physiological trajectories in ARDS: a retrospective cohort study.Frontiers in medicine · 2026Article
- Protective Effect of Modified Ginseng Baidu Powder Prophylactic Administration on LPS-Induced Acute Respiratory Distress Syndrome in Mice.Biochemical genetics · 2025Article
- Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS therapy.Science advances · 2025Article
- Effect of Regulating FUNDC1 Mitophagy-Mediated cGAS/STING Pathway in Oleic Acid-Induced Acute Lung Injury Model.Pulmonary circulation · 2025Article
- Impact of the duration of corticosteroid treatment for postoperative acute lung injury following lung cancer surgery.Journal of thoracic disease · 2025Article
- Microvesicles derived from mesenchymal stem cells inhibit acute respiratory distress syndrome-related pulmonary fibrosis in mouse partly through hepatocyte growth factor.World journal of stem cells · 2024Article
- IL-10 Counteracts IFN-γ to Alleviate Acute Lung Injury in a Viral-Bacterial Superinfection Model.American journal of respiratory cell and molecular biology · 2024Article
- Article
- Extracellular vesicles in acute respiratory distress syndrome: Understanding protective and harmful signaling for the development of new therapeutics.Histology and histopathology · 2024Review
- Article
- Pulmonary endothelium-targeted nanoassembly of indomethacin and superoxide dismutase relieves lung inflammation.Acta pharmaceutica Sinica. B · 2023Article
- Tidal lung hysteresis to interpret PEEP-induced changes in compliance in ARDS patients.Critical care (London, England) · 2023Article
- COVID-19 progression towards ARDS: a genome wide study reveals host factors underlying critical COVID-19.Genomics & informatics · 2023Article
- Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases.Acta pharmaceutica Sinica. B · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Care for patients with acute respiratory distress syndrome (ARDS) has changed considerably over the 50 years since its original description. Indeed, standards of care continue to evolve as does how this clinical entity is defined and how patients are grouped and treated in clinical practice. In this narrative review we discuss current standards - treatments that have a solid evidence base and are well established as targets for usual care - and also evolving standards - treatments that have promise and may become widely adopted in the future. We focus on three broad domains of ventilatory management, ventilation adjuncts, and pharmacotherapy. Current standards for ventilatory management include limitation of tidal volume and airway pressure and standard approaches to setting PEEP, while evolving standards might focus on limitation of driving pressure or mechanical power, individual titration of PEEP, and monitoring efforts during spontaneous breathing. Current standards in ventilation adjuncts include prone positioning in moderate-severe ARDS and veno-venous extracorporeal life support after prone positioning in patients with severe hypoxemia or who are difficult to ventilate. Pharmacotherapy current standards include corticosteroids for patients with ARDS due to COVID-19 and employing a conservative fluid strategy for patients not in shock; evolving standards may include steroids for ARDS not related to COVID-19, or specific biological agents being tested in appropriate sub-phenotypes of ARDS. While much progress has been made, certainly significant work remains to be done and we look forward to these future developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.